A six-week, three-period, randomized, double-blind, placebo-controlled crossover trial of 75 patients with narcolepsy found that modafinil 200 mg and 400 mg significantly increased objectively measured wakefulness (sleep latency on the Maintenance of Wakefulness Test, up 40% and 54% respectively versus placebo) and reduced daytime sleepiness measures, with more nausea and nervousness reported only at the 400 mg dose. It did not establish a substitute for sleep or long-term cognitive enhancement in healthy people.[1]
- Short disease-specific trial; absence of serious events in a modest trial is not a general safety guarantee.
- A 2021 European narcolepsy management guideline (Bassetti et al.) that continues to discuss modafinil's role was identified in this search but not inspected; recommended as follow-up to corroborate against contemporary evidence syntheses beyond this single 1997 trial.
- Abstract-checked; no qualified clinical review.
Inspection history
Clinical review: not reviewed by a qualified clinician.
· Prior batch record retained as unverified historical input pending fresh review.
· nootropic batch: reopened source(s) via NCBI E-utilities / PMC Open Access; verified and refined with precise numbers/limitations from the source.